奥来鲁单抗

奥来鲁单抗INN:oleclumab;开发代号:MEDI9447)是一种抗CD73单克隆抗体,旨在治疗胰腺癌结直肠癌和其他癌症。[1][2]

奥来鲁单抗
单克隆抗体
种类?
目标NT5E(或叫CD73)
临床资料
其他名称MEDI9447
ATC码
  • 未分配
识别信息
CAS号1803176-05-7
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6348H9826N1710O1998S40
摩尔质量143,350.81 g·mol−1

该药物由MedImmune/阿斯利康开发。[3]

参考资料

  1. ^ ClinicalTrial.gov for Oleclumab
  2. ^ Bendell, Johanna; LoRusso, Patricia; Overman, Michael; Noonan, Anne M.; Kim, Dong-Wan; Strickler, John H.; Kim, Sang-We; Clarke, Stephen; George, Thomas J.; Grimison, Peter S.; Barve, Minal. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer immunology, immunotherapy: CII. 2023-07, 72 (7) [2024-06-01]. ISSN 1432-0851. PMID 37016126. doi:10.1007/s00262-023-03430-6. (原始内容存档于2024-06-01). 
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab页面存档备份,存于互联网档案馆), American Medical Association.